11-chloro-5H-dibenzo[b,e][1,4]diazepine | 50373-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 11-chloro-5H-dibenzo[b,e][1,4]diazepine
• 英文别名: 6-chloro-11H-benzo[b][1,4]benzodiazepine
• CAS: 50373-21-2
• 化学式: C₁₃H₉ClN₂
• 分子量: 228.681
• InChiKey: RPJVCNBHEJVYKC-UHFFFAOYSA-N

物化性质

• 沸点：
  390.9±35.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  11-chloro-5H-dibenzo[b,e][1,4]diazepine 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 2.17h， 生成 4-(5H-dibenzo[b,e][1,4]diazepin-11-yl)-1-ethylpiperazine N-oxide
  参考文献：
  名称：

  The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs

  摘要：

  Over the past decade, two independent technologies have emerged and been widely adopted by the neuroscience community for remotely controlling neuronal activity: optogenetics which utilize engineered channelrhodopsin and other opsins, and chemogenetics which utilize engineered G protein-coupled receptors (Designer Receptors Exclusively Activated by Designer Drugs (DREADDs)) and other orthologous ligand receptor pairs. Using directed molecular evolution, two types of DREADDs derived from human muscarinic acetylcholine receptors have been developed: hM3Dq which activates neuronal firing, and hM4Di which inhibits neuronal firing. Importantly, these DREADDs were not activated by the native ligand acetylcholine (ACh), but selectively activated by dozapine N-oxide (CNO), a pharmacologically inert ligand. CNO has been used extensively in rodent models to activate DREADDs, and although CNO is not subject to significant metabolic transformation in mice, a small fraction of CNO is apparently metabolized to clozapine in humans and guinea pigs, lessening the translational potential of DREADDs. To effectively translate the DREADD technology, the next generation of DREADD agonists are needed and a thorough understanding of structure activity relationships (SARs) of DREADDs is required for developing such ligands. We therefore conducted the first SAR studies of hM3Dq. We explored multiple regions of the scaffold represented by CNO, identified interesting SAR trends, and discovered several compounds that are very potent hM3Dq agonists but do not activate the native human M3 receptor (hM3). We also discovered that the approved drug perlapine is a novel hM3Dq agonist with >10 000-fold selectivity for hM3Dq over hM3.

  DOI：

  10.1021/cn500325v
• 作为产物：
  描述：

  邻氨基苯甲酸 在 ammonium hydroxide 、 sodium dithionite 、 铜 、 potassium carbonate 、 N,N-二甲基苯胺 、 三氯氧磷 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 、 异戊醇 、 水 、 甲苯 为溶剂， 反应 55.5h， 生成 11-chloro-5H-dibenzo[b,e][1,4]diazepine
  参考文献：
  名称：

  The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs

  摘要：

  Over the past decade, two independent technologies have emerged and been widely adopted by the neuroscience community for remotely controlling neuronal activity: optogenetics which utilize engineered channelrhodopsin and other opsins, and chemogenetics which utilize engineered G protein-coupled receptors (Designer Receptors Exclusively Activated by Designer Drugs (DREADDs)) and other orthologous ligand receptor pairs. Using directed molecular evolution, two types of DREADDs derived from human muscarinic acetylcholine receptors have been developed: hM3Dq which activates neuronal firing, and hM4Di which inhibits neuronal firing. Importantly, these DREADDs were not activated by the native ligand acetylcholine (ACh), but selectively activated by dozapine N-oxide (CNO), a pharmacologically inert ligand. CNO has been used extensively in rodent models to activate DREADDs, and although CNO is not subject to significant metabolic transformation in mice, a small fraction of CNO is apparently metabolized to clozapine in humans and guinea pigs, lessening the translational potential of DREADDs. To effectively translate the DREADD technology, the next generation of DREADD agonists are needed and a thorough understanding of structure activity relationships (SARs) of DREADDs is required for developing such ligands. We therefore conducted the first SAR studies of hM3Dq. We explored multiple regions of the scaffold represented by CNO, identified interesting SAR trends, and discovered several compounds that are very potent hM3Dq agonists but do not activate the native human M3 receptor (hM3). We also discovered that the approved drug perlapine is a novel hM3Dq agonist with >10 000-fold selectivity for hM3Dq over hM3.

  DOI：

  10.1021/cn500325v

文献信息

• Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase
  申请人：Forum Pharmaceuticals, Inc.

  公开号：US20170000749A1

  公开（公告）日：2017-01-05

  This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  这份披露涉及用于抑制组蛋白去乙酰化酶和治疗认知障碍或缺陷的化合物。更具体地，该披露提供了公式（I）的化合物 其中 Q、J、L和Z如规范中所定义。
• Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds
  申请人：Ali Syed M.

  公开号：US20110245236A1

  公开（公告）日：2011-10-06

  The present invention relates to substituted benzo-pyrido-triazolo-diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted benzo-pyrido-triazolo-diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof.

  本发明涉及替代苯并吡啶三唑二氮杂环己烷化合物及其合成方法。本发明还涉及含有替代苯并吡啶三唑二氮杂环己烷化合物的药物组合物，以及通过向需要的受试者施用这些化合物或药物组合物来治疗细胞增殖性疾病，如癌症的方法。
• Inhibitors of Histone Deacetylase
  申请人：Deziel Robert

  公开号：US20080207590A1

  公开（公告）日：2008-08-28

  This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  该发明涉及用于抑制组蛋白去乙酰化酶的化合物。更具体地，该发明提供了式（I）中Q、J、L和Z所定义的化合物。
• METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE
  申请人：Rogers Kathryn

  公开号：US20110288070A1

  公开（公告）日：2011-11-24

  This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein (I), Q, J, L and Z are as defined in the specification.

  本公开涉及化合物用于抑制组蛋白去乙酰化酶并治疗认知障碍或缺陷。更具体地，本公开提供了式（I）的化合物，其中（I），Q，J，L和Z如规范中所定义。
• INHIBITORS OF HISTONE DEACETYLASE
  申请人：Déziel Robert

  公开号：US20110196147A1

  公开（公告）日：2011-08-11

  This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  本发明涉及用于抑制组蛋白去乙酰化酶的化合物。更具体地，本发明提供了公式（I）中Q、J、L和Z所定义的化合物。